Abstract

A REVIEW ON NOVEL ORAL ANTICOAGULANTS ROLE IN PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM COMPLICATIONS IN CLINICAL SETTINGS

S. Aishwarya*, B. Mothishwaran and S. Uma

Abstract

Venous thromboembolism (VTE) which consists principally of deep vein thrombosis (DVT) and pulmonary embolism (PE) is a common cause of morbidity and mortality. Venous thromboembolism (VTE), which includes DVT and pulmonary embolism (PE), affects 1 per 1,000 people and contributes to 60,000–100,000 deaths annually. Normal blood physiology depends on a delicate balance between proand anti-coagulant factors. Virchow’s Triad distills the multitude of risk factors for DVT into three basic elements favoring thrombus formation includes venous stasis, vascular injury, and hypercoagulability. Clinical, biochemical, and radiological examinations are used to detect the incidence of deep vein thrombosis in the community. Deep venous thrombosis is a life threatening condition. Administration of oral anticoagulants can lower the future occurrence of disease complications. Early assessment of an individual patient’s risk factors, clinical history, interacting medications, can enhance the therapeutic outcomes of individuals. Novel drugs for the treatment of deep vein thrombosis include the direct factor Xa inhibitors, rivaroxaban, apixaban can prevent the future occurrence of deep vein thrombosis complications in the society.

Keywords: Venous thromboembolism, pulmonary embolism, venous stasis, vascular injury, anti-coagulants.